PS-106-An international, randomized, placebo-controlled phase 2 trial demonstrates novel effects of DGAT2 antisense inhibition in reducing steatosis without causing hypertriglyceridemia in T2DM patients

Published 2019 View Full Article

Authors

Keywords

Journal

JOURNAL OF HEPATOLOGY

Volume 70, Issue 1, Pages e67-e68

Publisher

Elsevier BV

Online

2019-04-16

DOI

10.1016/s0618-8278(19)30118-5

Ask authors/readers for more resources

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started

JOURNAL OF HEPATOLOGY

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Create your own webinar

Ask a Question. Answer a Question.